Targeted Naltrexone in Asia-Pacific: What Access Evidence Shows
Targeted naltrexone has trial evidence, but local access depends first on whether standalone naltrexone is marketed and whether a clinician supports the protocol.
What to verify before booking
- Trial evidence exists for targeted dosing, but there is no universal 78% success rate.
- Product availability and protocol acceptance are different questions.
- A registered Contrave product does not create a targeted addiction-treatment pathway.
- Public funding rules may not cover every off-label dosing approach.
- Provider directories and clinic marketing are not substitutes for regulator or pharmacy confirmation.
Country evidence snapshot, checked 26 July 2026
| Country | Standalone product evidence | What targeted access means |
|---|---|---|
| Australia | TGA/PBS evidence for 50 mg oral naltrexone | A clinician may consider targeted dosing; confirm whether prescribing and PBS eligibility match the intended use |
| New Zealand | Pharmac funds 50 mg tablets under SA1408 for people in a comprehensive alcohol-dependence treatment programme; Naltraccord or Naltrexone-GH until 1 November 2026, then Naltrexone Lupin | A prescriber must check current Special Authority criteria and whether the proposed dosing plan fits funding and clinical practice |
| Singapore | Contrave SIN16411P verified; currently marketed standalone 50 mg product not verified | Do not assume targeted treatment is routinely available; ask NAMS or a clinician and pharmacy for the exact product |
| UAE | Active Contrave entry verified; standalone naltrexone not found in the live EDE search | DHA guidance names naltrexone clinically, but a clinician must verify a lawful supply route |
What the clinical evidence says
The 2001 Heinälä trial involved 121 participants and included 12 weeks of daily medication followed by a targeted phase; it was not a “78% success” meta-analysis. A 2022 placebo-controlled trial in 120 sexual and gender minority men found benefits on binge-drinking and several secondary outcomes over 12 weeks.
Those trials justify informed discussion. They do not establish a guaranteed pharmacological-extinction timeline or prove that targeted dosing is superior for every person.
Questions to ask
- Which exact standalone product and strength can be dispensed?
- Is targeted dosing supported by the clinician and local label or guidelines?
- Does any public or insurance funding apply to this dosing approach?
- How will heavy-drinking days, adverse effects, and adherence be reviewed?
- What is the plan after missed doses, unplanned drinking, opioid pain treatment, or no improvement?
Sources
- Heinälä et al., 2001 randomized trial
- Santos et al., 2022 randomized trial
- Australia PBS item 8370M
- PHARMAC Schedule, June 2026 (PDF)
- Naltrexone tab 50 mg: Your brand is changing — Pharmac, last updated 12 October 2026. New Zealand row updated 22 October 2026.
- Singapore National Drug Formulary: Contrave
- UAE EDE Drug Directory